Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 1
2020 3
2021 7
2022 8
2023 5
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Extended dosing of monoclonal antibodies in multiple sclerosis.
van Kempen ZL, Toorop AA, Sellebjerg F, Giovannoni G, Killestein J. van Kempen ZL, et al. Among authors: toorop aa. Mult Scler. 2022 Nov;28(13):2001-2009. doi: 10.1177/13524585211065711. Epub 2021 Dec 24. Mult Scler. 2022. PMID: 34949134 Review.
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
Toorop AA, van Lierop ZY, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, van Munster CE, Vennegoor A, Mostert JP, Wokke BH, Kalkers NF, Hoogervorst EL, van Eijk JJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige L, Kloosterziel ME, Arnoldus EP, van Dijk GW, Bouvy WH, Wessels MH, Boonkamp L, Strijbis EM, van Oosten BW, De Jong BA, Lissenberg-Witte BI, Barkhof F, Moraal B, Teunissen CE, Rispens T, Uitdehaag BM, Killestein J, van Kempen ZL. Toorop AA, et al. J Neurol Neurosurg Psychiatry. 2024 Apr 12;95(5):392-400. doi: 10.1136/jnnp-2023-332119. J Neurol Neurosurg Psychiatry. 2024. PMID: 37963723 Clinical Trial.
The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis.
Toorop AA, van Lierop ZYGJ, Strijbis EMM, Teunissen CE, Barkhof F, Uitdehaag BMJ, van Kempen ZLE, Killestein J. Toorop AA, et al. Mult Scler Relat Disord. 2022 Jan;57:103364. doi: 10.1016/j.msard.2021.103364. Epub 2021 Nov 1. Mult Scler Relat Disord. 2022. PMID: 35158470 Free article.
Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
van Lierop ZY, Noteboom S, Steenwijk MD, van Dam M, Toorop AA, van Kempen ZL, Moraal B, Barkhof F, Uitdehaag BM, Schoonheim MM, Teunissen CE, Killestein J. van Lierop ZY, et al. Among authors: toorop aa. Mult Scler. 2022 Dec;28(14):2231-2242. doi: 10.1177/13524585221118676. Epub 2022 Sep 3. Mult Scler. 2022. PMID: 36062492 Free PMC article.
Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients.
van Lierop Z, Toorop AA, Coerver E, Willemse E, Strijbis E, Kalkers NF, Moraal B, Barkhof F, Teunissen CE, Killestein J, van Kempen Z. van Lierop Z, et al. Among authors: toorop aa. Mult Scler J Exp Transl Clin. 2021 Jun 1;7(2):20552173211013831. doi: 10.1177/20552173211013831. eCollection 2021 Apr-Jun. Mult Scler J Exp Transl Clin. 2021. PMID: 34123391 Free PMC article.
22 results